Income Statement Ovoca Bio plc Euronext Dublin
Equities
OVXA
IE0006649010
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0100 EUR | -.--% |
|
-.--% | - |
| Feb. 24 | Talisman Metals acquires two Morocco copper licences for GBP16,000 | AN |
| Feb. 24 | Talisman Metals Starts Exploration at Fougnar Copper-silver Project in Morocco | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Selling General & Admin Expenses, Total | 2.2M | 6.1M | 5.42M | 1.87M | 658K | |||||
Provision for Bad Debts | - | - | - | - | - | |||||
R&D Expenses | - | - | - | - | - | |||||
Depreciation & Amortization - (IS) | - | - | - | - | - | |||||
Other Operating Expenses | - | -236K | -1.46M | -1.02M | -409K | |||||
Other Operating Expenses, Total | 2.2M | 5.86M | 3.97M | 849K | 249K | |||||
Operating Income | -2.2M | -5.86M | -3.97M | -849K | -249K | |||||
Interest Expense, Total | -16K | -21K | -39K | -5K | - | |||||
Interest And Investment Income | 231K | 104K | 4K | - | - | |||||
Net Interest Expenses | 215K | 83K | -35K | -5K | - | |||||
Currency Exchange Gains (Loss) | -332K | 530K | -1.28M | 46K | 246K | |||||
EBT, Excl. Unusual Items | -2.32M | -5.25M | -5.28M | -808K | -3K | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | -19K | - | - | |||||
Gain (Loss) On Sale Of Assets | 4K | - | -313K | - | - | |||||
Asset Writedown | - | - | - | -4.3M | - | |||||
EBT, Incl. Unusual Items | -2.32M | -5.25M | -5.61M | -5.1M | -3K | |||||
Earnings From Continuing Operations | -2.32M | -5.25M | -5.61M | -5.1M | -3K | |||||
Earnings Of Discontinued Operations | -54K | -228K | - | 402K | -743K | |||||
Net Income to Company | -2.37M | -5.48M | -5.61M | -4.7M | -746K | |||||
Minority Interest | 36K | - | - | - | - | |||||
Net Income - (IS) | -2.34M | -5.48M | -5.61M | -4.7M | -746K | |||||
Net Income to Common Incl Extra Items | -2.34M | -5.48M | -5.61M | -4.7M | -746K | |||||
Net Income to Common Excl. Extra Items | -2.28M | -5.25M | -5.61M | -5.1M | -3K | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.09 | -0.2 | -0.21 | -0.17 | -0.03 | |||||
Basic EPS - Continuing Operations | -0.08 | -0.19 | -0.21 | -0.19 | -0 | |||||
Basic Weighted Average Shares Outstanding | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | |||||
Net EPS - Diluted | -0.09 | -0.2 | -0.21 | -0.17 | -0.03 | |||||
Diluted EPS - Continuing Operations | -0.08 | -0.19 | -0.21 | -0.19 | -0 | |||||
Diluted Weighted Average Shares Outstanding | 27.19M | 27.19M | 27.19M | 27.19M | 27.19M | |||||
Normalized Basic EPS | -0.05 | -0.12 | -0.12 | -0.02 | -0 | |||||
Normalized Diluted EPS | -0.05 | -0.12 | -0.12 | -0.02 | -0 | |||||
Supplemental Items | ||||||||||
EBITDA | -2.13M | -5.78M | -3.62M | -549K | 51K | |||||
EBITA | -2.14M | -5.78M | -3.62M | -549K | -249K | |||||
EBIT | -2.2M | -5.86M | -3.97M | -849K | -249K | |||||
EBITDAR | -2.11M | -5.72M | -3.6M | - | - | |||||
Normalized Net Income | -1.42M | -3.28M | -3.3M | -505K | -1.88K | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 2.18M | 6.04M | 5.41M | 1.87M | 658K | |||||
Research And Development Expense From Footnotes | 688K | 3.55M | 2.46M | 419K | - | |||||
Net Rental Expense, Total | 22K | 56K | 15K | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 9K | 12K | 4K | - | - | |||||
Total Stock-Based Compensation | 9K | 12K | 4K | - | - |
- Stock Market
- Equities
- TLM Stock
- OVXA Stock
- Financials Ovoca Bio plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















